F S&P 500
5,538.75 +1.75 (+0.03%) F Dow Jones
39,512.00 -14.00 (-0.04%) F Nasdaq
19,988.00 +15.75 (+0.08%) E-mini Russell 2000 Index Futur
2,044.30 -0.60 (-0.03%) Petróleo
81.19 +0.36 (+0.45%) Oro
2,332.00 +1.20 (+0.05%)
VITA 34 AG (VTIAF)
VITA 34 AG
Deutscher Platz 5a
Leipzig 04103
Germany
49 341 48792 40
https://www.vita34.de
Sector(es): Healthcare
Industria: Medical Care Facilities
Empleados a tiempo completo: 758
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Jakub Julian Baran | Chairman of the Management Board & CEO | N/D | N/D | N/D |
| Mr. Tomasz Franciszek Baran | Vice President of the Management Board & Chief Commercial Officer | N/D | N/D | N/D |
| Santiago Luengo | Managing Director of Secuvita | N/D | N/D | N/D |
Descripción
VITA 34 AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces and manufactures viral vectors and CAR-T cells. In addition, the company provides biobanking services, such as freezing sperm and storage of adipose tissue and the isolation of cells from the stored materials. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.
Gestión corporativa
La calificación ISS Governance QuickScore de VITA 34 AG a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
